Á¦51ȸ Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ Ãß°èÇмú´ëȸ : 2021-11-27±³À°ÀÏÀÚ : 2021-11-27
±³À°Àå¼Ò : ¿Â¶óÀÎ(½Ç½Ã°£ È»ó °ÀÇ), ¿ÀÇÁ¶óÀÎ(±×·£µå ¿öÄ¿Èú, ¼¿ï)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ ¿ÀÇÁ¶óÀÎ º´Çà) Á¦51ȸ Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ
´ã´çÀÚ : ±è´ÙÇý
¿¬¶ôó : 02-3147-0930
À̸ÞÀÏ :
ksecho4@ksecho.org ±³À°Á¾·ù : ³»°úÀÇÇб³À°
Âü¼®¿¹»óÀοø : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 18ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í [¿ÀÇÁ¶óÀÎ-(°³¿ø)Àü¹®ÀÇ,ÀüÀÓÀÇ,±ºÀÇ°ü µî 8¸¸¿ø / Àü°øÀǹױ⟠4¸¸¿ø][¿Â¶óÀÎ-(°³¿ø)Àü¹®ÀÇ,ÀüÀÓÀÇ,±ºÀÇ°ü µî 2¸¸¿ø / Àü°øÀǹױ⟠1¸¸¿ø]
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 09:00~09:15 Updates in the diagnosis and echo approach ¹®Á¤±Ù(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 09:15~09:30 Risk of sudden death ±èÇü°ü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 09:30~09:45 Novel treatment approach ¾çµ¿Çå(°æºÏÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 09:45~10:00 Surgery for HCM ±è°æȯ(¼¿ïÀÇ´ë)
Åä·Ð 11-27 ºñ½ºÅ¸2 10:00~10:20 Panel Discussion ()
ÈÞ½Ä 11-27 ºñ½ºÅ¸2 10:20~10:50 Coffee Break ()
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 10:50~11:03 Association of anti-citrullinated peptide antibodies with the progression of aortic stenosis ±è¾Æ¶÷(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 11:03~11:16 Late leaflet thrombosis after transcatheter aortic valve replacement ¹Ú¹ÎÁ¤(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 11:16~11:29 Adjustment of Pressure Recovery versus Aortic Valve Calcium Score to Improve Concordance in Severity Assessment in Patients with Predominantly Severe Aortic Stenosis Impact of Different Race ¿ÀÁø°æ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 11:29~11:42 Echocardiographic diastolic parameters as a predictor of Cardiovascular events after living donor kidney transplantation. À±ÇöÁö(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 11:42~11:55 Non-invasive estimation of left atrial pressure in patients with atrial fibrillation ¼Áö¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-27 11:55~12:08 Long-term prognostic value of reduced and borderline left ventricular ejection fraction in hypertrophic cardiomyopathy ÃÖÀ¯Á¤(¼¿ïÀÇ´ë)
±âŸ 11-27 ºñ½ºÅ¸2 12:10~12:15 Opening ()
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 12:15~12:35 Protecting Patients with DM and NVAF ¹è¸íȯ(°æºÏÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 12:35~12:55 Protecting Patients with Cancer Associated Thrombosis ±èÀº°æ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 12:55~13:15 Protecting Patients with Poly-vascular disease ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë)
±âŸ 11-27 ºñ½ºÅ¸2 13:15~13:20 Closing ()
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 13:20~13:40 HF ±èÀÎö(°è¸íÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 13:40~14:00 Valvular Heart Disease Çã¶õ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 14:00~14:20 Coronary Heart Disease ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 14:20~14:40 Atrial Fibrillation ÃÖÁ¾ÀÏ(°í·ÁÀÇ´ë)
ÈÞ½Ä 11-27 ºñ½ºÅ¸2 14:40~15:10 Coffee Break ()
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 15:10~15:25 Pulmonary hypertension and evaluation of right heart cirulcation system ¼ÛÁ¾¹Î(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 15:25~15:40 Pulmonary arterial hypertension: Update ÃÖÁ¤Çö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 15:40~15:55 Combined pre and post-capillary pulmonary hypertension Á¶À翵(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-27 ºñ½ºÅ¸2 15:55~16:10 Pulmonary thromboembolism : acute and chronic À强¾Æ(¼º±Õ°üÀÇ´ë)
Åä·Ð 11-27 ºñ½ºÅ¸2 16:10~16:30 Panel Discussion ()